Related Experiment Video

Updated: May 25, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Phase II studies in soft tissue sarcoma: time for reappraisal

Stefan Sleijfer1

  • 1Department of Medical Oncology, Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands. s.sleijfer@erasmusmc.nl

The Oncologist
|January 31, 2012
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Related Experiment Videos

Last Updated: May 25, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

Circulating Tumor Cells Enhance Prognostic Stratification Beyond ER Assessment by Biopsy or FES-PET in Endocrine-Treated Metastatic Breast Cancer.

Diagnostics (Basel, Switzerland)·2026

Prognostic value of peri-operative circulating tumour DNA levels estimated by cell-free DNA methylation in patients with resectable colorectal liver metastases.

EBioMedicine·2026

Circulating tumour cells & circulating tumour DNA in patients with resectable colorectal liver metastases (MIRACLE): a prospective, observational biomarker study.

EClinicalMedicine·2025

Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

A review of trials investigating ctDNA-guided adjuvant treatment of solid tumors: The importance of trial design.

European journal of cancer (Oxford, England : 1990)·2024

Comprehensive characterization of circulating tumor cells and cell-free DNA in patients with metastatic melanoma.

Molecular oncology·2024

Genomic Landscape and Therapeutic Implications of ALK Fusion-Positive Colorectal Cancer.

The oncologist·2026

Oncofertility in Gastrointestinal (GI) Oncology - A Pan-European study of the patient perspective.

The oncologist·2026

A Silent Gap: Underrepresentation of Latin American Patients in Pivotal Genitourinary and Skin Cancer Trials.

The oncologist·2026

HopeFOL, or FOL of Problems? Leucovorin For Autistic Symptoms.

The oncologist·2026

Genomic landscape and clinical characteristics of ERBB2/HER2-mutated colorectal cancers.

The oncologist·2026

Chemical Exposures as Risk Factors for the Development of Thyroid Cancer.

The oncologist·2026

Unveiling the biochemical signature of tumor-induced osteomalacia: implications for distinguishing it from primary osteoporosis.

Frontiers in endocrinology·2026

Chondroid Soft Tissue Tumors With FOS::PABPN1 Fusion: A New Entity? About Two Cases.

Genes, chromosomes & cancer·2026

Targeting ABCB6 induces ferroptosis in osteosarcoma cells via HIF1A/GPX4 pathway.

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences·2026

Mood computational mechanisms underlying increased risk behavior in adolescent suicidal patients.

eLife·2026

Modeling of Patient-Derived 3D Organoids of Thyroid Cancer: From Cells to Care.

International journal of endocrinology·2026

A Solitary Soft Tissue Mass in the Thigh as the First Manifestation of Occult Lung Squamous Cell Carcinoma: A Case Report.

Respirology case reports·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us